feburic怎么吃？

The pain of gout comes and goes just as quickly as the wind, but when a gout attack occurs, it is really life-threatening. (Febuxostat) is an acid-lowering drug commonly used by gout patients, but not all gout patients can use it. feburic (febuxostat) is mainly suitable for the long-term treatment of hyperuricemia in patients with gout, and is not recommended for use in asymptomatic hyperuricemia. How to eat feburic?

According to the labeling, the starting dose of feburic (febuxostat) is 40 mg orally once daily. If the serum uric acid level is still not less than 360 umol/L after 2 weeks, it is recommended to increase the dose to 80 mg once daily. It is recommended to take the medicine for at least 6 months to prevent acute attacks of gout. If gout occurs during treatment with this drug, there is no need to discontinue the drug.

Pediatric Use: The safety and effectiveness of this product in treating patients under 18 years of age have not been established.

Elderly patients: No dosage adjustment is required for elderly patients. According to foreign literature reports, in clinical studies of feburic (febuxostat), people aged 65 and over accounted for 16% of the total number of subjects, and people aged 75 and over accounted for 4%. Comparing subjects of different age groups, there is no clinically significant difference in effectiveness and safety, but it cannot be ruled out that some elderly patients are more sensitive to this product. After multiple oral administrations of feburic (febuxostat) to elderly subjects (65 years and above), Cmax and AUC24 were similar to those of young subjects (18 to 40 years old).

Since feburic (febuxostat) is mainly metabolized in the liver, 49% of metabolized inactive substances are excreted through the kidneys, 45% through feces, and some are excreted through bile, which is a multi-pathway excretion. Therefore, the dosage does not need to be adjusted in patients with mild or moderate renal failure (endogenous creatinine clearance 30-89 mL/min) and mild or moderate (Child-Pugh Class A and B) hepatic impairment.

The 2013 version of the "Chinese Expert Consensus on the Treatment of Hyperuricemia and Gout" recommends that if monotherapy cannot achieve the target of serum uric acid, combination therapy can be carefully considered. If feburic (febuxostat) still cannot achieve treatment goals after increasing to an appropriate dose (generally to 80 mg/day), another drug that promotes uric acid excretion can be used in combination. It should be noted that (febuxostat) may cause increased blood concentrations of azathioprine, mercaptopurine and theophylline and increase toxicity.